Navigation Links
Insmed to Present at 2011 Wedbush Securities Life Sciences Management Access Conference
Date:8/11/2011

uch factors as the receipt and timing of FDA and other regulatory reviews and approvals, if at all, competitive developments affecting our product development, delays in product development or clinical trials, and patent disputes involving currently developing products.  The risks and uncertainties include, without limitation, we may experience unexpected regulatory actions, delays or requests, our future clinical trials may not be successful, we may be unsuccessful in developing our product candidates or receiving necessary regulatory approvals, we may experience delays in our product development or clinical trials, our product candidates may not prove to be commercially successful, our expenses may be higher than anticipated and other risks and challenges detailed in our filings with the U.S. Securities and Exchange Commission, including our Annual Report on Form 10-K for the year ended December 31, 2010 and our Quarterly Report on Form 10-Q for the quarter ended June 30, 2011.  Investors are cautioned not to place undue reliance on any forward-looking statements which speak only as of the date of this release.  We undertake no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this release or to reflect the occurrence of unanticipated events.

Investor Relations Contact:
Brian Ritchie - FD
212-850-5683
brian.ritchie@fd.com

Media Contact:
Irma Gomez-Dib - FD
212-850-5761
irma.gomez-dib@fd.com


'/>"/>
SOURCE Insmed Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Andrea Drucker Joins Insmed as General Counsel
2. Insmed Announces FDA Clearance of IND for Pivotal Phase 3 Trial of ARIKACE™ in Nontuberculous Mycobacteria Indication
3. Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
4. Insmed to Host Second Quarter 2009 Conference Call
5. Insmed Announces Addition to the Russell 3000(R) Index
6. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
7. Insmed CEO Resigns Due to Health Concerns
8. Insmed Announces First Quarter 2009 Financial Results
9. Insmed Regains NASDAQ Compliance
10. Insmed to Host First Quarter 2009 Conference Call
11. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... Iowa (PRWEB) September 02, 2014 Press ... of ways to take advantage of the people and ... the schedule below are available throughout the day. Additionally, ... requests with POET and DSM representatives as well as ... interview requests is appreciated. , Please remember to ...
(Date:9/2/2014)... 02, 2014 Myriant Corporation, a ... of a distribution agreement with Azelis Group, a ... Myriant’s bio-succinic acid in the Nordics, Benelux, France, ... customers in the industrial and base chemicals markets. ... offers a far-reaching chemical portfolio with extensive distribution ...
(Date:9/2/2014)... Inc. (Nasdaq: ONTY ) announced today that ... present at the Rodman & Renshaw 16 th Annual ... on Tuesday, Sept. 9, 2014 at 2:05 p.m. Eastern. ... will be accessible by visiting the Oncothyreon website www.oncothyreon.com ... About Oncothyreon Oncothyreon is a biotechnology company ...
(Date:9/2/2014)...  Spherix Incorporated (SPEX) -- an intellectual property development company committed ... announced that the United States Patent & Trademark Office ... month of August that are part of a standard ... patents are: , U.S.RE45,065 issued August ... and , U.S.RE45,095 issued August 26, 2014.  ...
Breaking Biology Technology:Press agenda for Project LIBERTY Grand Opening 2Press agenda for Project LIBERTY Grand Opening 3Press agenda for Project LIBERTY Grand Opening 4Press agenda for Project LIBERTY Grand Opening 5Myriant and Azelis Sign European Distribution Agreement for Bio-Succinic Acid 2United States Patent & Trademark Office Issues Three New Standard Essential Patents to Spherix 2
... For Women in Science program is welcoming the 15 International Fellows ... , On Wednesday, March 28, from 4 pm to ... the Pasteur Institute in Paris. Following these presentations, a cocktail ... be met individually , , On ...
... physics of massive particles has intrigued physicists for more than ... exhibit wave-like behaviour in conflict with our everyday ideas ... of scientists now succeeded in shooting a movie which shows ... molecules which is so large (up to 0.1 mm) that ...
... March 22, 2012 /PRNewswire-iReach/ -- FirstMark, the ... announce that the company will be exhibiting at the ... College of Cardiology (ACC) in Chicago, March 24-27, Booth ... PREvent is the first and only multiple biomarker blood ...
Cached Biology Technology:The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 2The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 3The 14th Annual L'Oréal-Unesco Awards or Women on Science: From March 26 to March 29, Paris Welcomes and Honours Tomorrow's Scientific Talents 4Single molecules in a quantum movie 2FirstMark Exhibiting at the American College of Cardiology 61st Annual Scientific Sessions & Expo 2
(Date:9/2/2014)... milk is considered the most ideal source of ... a critical role in the evolution and civilizations ... milk contains a large number of bacterial species, ... comes as no surprise to scientists and physicians. ... considered to be the result of co-evolutionary and ...
(Date:9/2/2014)... between our immune systems and cholera bacteria, humans may ... phages. In a new study, researchers from Tufts University, ... Health Laboratory, and elsewhere, report that phages can force ... to survive. Importantly, the study published in ... phage predation occurs during human infection. , First author ...
(Date:9/2/2014)... the price of your integrity? Tell the truth; everyone has ... at some point, we,ll lie if the benefit is great ... in which we make that decision. , The result ... . , "We prefer to be honest, even if ... and a postdoctoral associate at the Virginia Tech Carilion ...
Breaking Biology News(10 mins):Are human breast milk microbiome 'neutral'? 2Are human breast milk microbiome 'neutral'? 3War between bacteria and phages benefits humans 2War between bacteria and phages benefits humans 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 2Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 3Scientists find possible neurobiological basis for tradeoff between honesty, self-interest 4
... Medicine researchers played a key role in the largest ... 11 new regions of the genome that contribute to ... therapeutic targets to investigate. Published October 27 in ... of the genetic factors contributing to Alzheimer,s and expands ...
... A group of students and faculty at Grand Valley State ... new methods to further a growing medical field that aims ... group of four Grand Valley students and graduates, and Anthony ... the World Molecular Imaging Congress, one of the largest meetings ...
... Ore. -- (Oct. 25, 2013) -- Twenty grams of essential amino ... weeks after knee-replacement surgeries helped 16 patients, mean age 69, recover ... ingesting a placebo. The approach -- detailed in a paper ... the Journal of Clinical Investigation -- could spell relief ...
Cached Biology News:International collaboration finds 11 new Alzheimer's genes to target for drug discovery 2GVSU students contribute to growing medical field 2Oregon researchers say supplement cuts muscle loss in knee replacements 2Oregon researchers say supplement cuts muscle loss in knee replacements 3Oregon researchers say supplement cuts muscle loss in knee replacements 4
...
Human/Mouse/Rat p38 alpha Affinity Purified PAb...
sterile filtered, off the clot, all male donors, Total Protein: 4.5 to 8.5 g/dl...
Human alpha-1-antitrypsin. No cross-reactivity with alpha-1-acid glycoprotein, serum albumin or other serum proteins....
Biology Products: